DDInter1701 DDInter782
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Sonidegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Sonidegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Sonidegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Sonidegib {u} may lead to a major life threatening interaction when taken with {v} Duvelisib
Sonidegib {u} may lead to a major life threatening interaction when taken with {v} Nafcillin
Sonidegib may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Sonidegib may lead to a major life threatening interaction when taken with Duvelisib
Sonidegib may lead to a major life threatening interaction when taken with Nafcillin